Targeted photodynamic therapy

Lasers in Surgery and Medicine

Volumn 38, Issue 5, 2006, Pages 522-531

  Solban, Nicolas ^a   Rizvi, Imran ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Photodynamic therapy; Photosensitizer; Targeted delivery

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; CETUXIMAB; COLLAGEN; DEFEROXAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FERROCHELATASE; GLUCOSE 6 PHOSPHATE; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GROWTH FACTOR RECEPTOR; HEME; INSULIN RECEPTOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSOSOME ENZYME; METHOTREXATE; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; POLYVINYL ALCOHOL; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; TETRASULFOPHTHALOCYANINE ALUMINUM; TRANSFERRIN; TRANSFERRIN RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CLINICAL TRIAL; FLUORESCENCE; GENE; HUMAN; HYDROPHOBICITY; IMMUNOTHERAPY; NEOPLASM; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33745714000     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20345     Document Type: Article

References (65)

1. Solban N, Ortel B, Pogue B, Hasan T. Targeted optical imaging and photodynamic therapy. Ernst Schering Res Found Workshop 2005;12(49):229-258.
2. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508.
3. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
4. Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J Photochem Photobiol B, Biol 1998;42:89-95.
5. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997;65:422-426.
6. Dahle J, Steen HB, Moan J. The mode of cell death induced by photodynamic treatment depends on cell density. Photochem Photobiol 1999;70:363-367.
7. Wood SR, Holroyd JA, Brown SB. The subcellular localization of Zn(II) phthalocyanines and their redistribution on exposure to light. Photochem Photobiol 1997;65:397-402.
8. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20:3-7.
9. Molpus KL. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res 1996;56:1075-1082.
10. Freitas I. Lipid accumulation: The common feature to photosensitizer- retaining normal and malignant tissues. J Photochem Photobiol B 1990;7:359-361.
11. Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005;61:1216-1226.
12. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002;66:89-106.
13. Chen B, Pogue BW, Hasan T. Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2005;2:477-487.
14. Oenbrink G, Jurgenlimke P, Gabel D. Accumulation of porphyrins in cells: Influence of hydrophobicity aggregation and protein binding. Photochem Photobiol 1988;48:451-456.
15. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994;69:833-839.
16. Barel A, Jori G, Perin A, Romandini P, Pagnan A, Biffanti S. Role of high-, low- and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett 1986;32:145-150.
17. Kessel D, Whitcomb KL, Schulz V. Lipoprotein-mediated distribution of N-aspartyl chlorin-E6 in the mouse. Photochem Photobiol 1992;56:51-56.
18. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 1993;57:1000-1006.
19. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 1988;80:1599-1605.
20. Lopez RF, Lange N, Guy R, Bentley MV. Photodynamic therapy of skin cancer: Controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004;56:77-94.
21. Casas A, Batlle A. Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy. Curr Med Chem Anti-Canc Agents 2002;2:465-475.
22. Tan WC, Krasner N, O'Toole P, Lombard M. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron. Gut 1997;41:14-18.
23. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer 1996;74:688-697.
24. Choudry K, Brooke RC, Farrar W, Rhodes LE. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 2003;149:124-130.
25. Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br J Cancer 1998;78:1278-1282.
26. Iinuma S, Farshi SS, Ortel B, Hasan T. A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin [published erratum appears in Br J Cancer 1994 Dec;70(6):1283]. Br J Cancer 1994;70:21-28.
27. Ortel B, Sharlin D, O'Donnell D, Sinha AK, Maytin EV, Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 2002;87:1321-1327.
28. Ortel B, Chen N, Brissette J, Dotto GP, Maytin E, Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin DC accumulation in primary mouse keratinocytes. Br J Cancer 1998;77:1744-1751.
29. Li G, Szewczuk MR, Pottier RH, Kennedy JC. Effect of mammalian cell differentiation on response to exogenous 5-aminolevulinic acid. Photochem Photobiol 1999;69:231-235.
30. Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci USA 1992;89:594-598.
31. Bodner AJ, Ting RC, Gallo RC. Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. J Natl Cancer Inst 1981;67:1025-1030.
32. Savellano MD, Hasan T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem Photobiol 2003;77:431-439.
33. Savellano MD, Hasan T. Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin Cancer Res 2005;11:1658-1668.
34. Hasan T, Lin A, Yarmush D. Monoclonal antibody-chromophore conjugates as selective phototoxins. J Controlled Release 1989;10:107-117.
35. Yarmush ML, Thorpe WP, Strong L, Rakestraw SL, Toner M, Tompkins RG. Antibody targeted photolysis. Crit Rev Ther Drug Carrier Syst 1993;10:197-252.
36. Jiang FN, Jiang S, Liu D, Richter A, Levy JG. Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods 1990;134:139-149.
37. vrouenraets MB, Visser GW, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart F, Snow GB, van Dongen GA. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodznamic therapy. Int J Cancer 2000;88:108-114.
38. Vrouenraets MB, Visser GW, Stigter M, Opelaar H, Snow GB, van Dongen GA. Targeting of aluminium (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies:improved efficacy in photodynamic therapy. Cancer Res 2001;61:1970-1975.
39. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, Hasan T. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 2001;61:4490-4496.
40. Shin DM, Gimenez IB, Lee JS, Nishioka K, Wargovich MJ, Thacher S, Lotan R, Slaga TJ, Hong WK. Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Cancer Res 1990;50:2505-2510.
41. Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 2005;65:6371-6379.
42. del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B, Hasan T. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005;97:1516-1524.
43. Cengel KA, Hahn SM, Glatstein E. C225 and PDT combination therapy for ovarian cancer: The play's the thing. J Natl Cancer Inst 2005;97:1488-1489.
44. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol 1995;19:183-232.
45. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98.
46. Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller AF Jr., Hasan T. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer 1996;68:588-595.
47. Gijsens A, Missiaen L, Merlevede W, de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 2000;60:2197-2202.
48. Akhlynina TV, Rosenkranz AA, Jans DA, Sobolev AS. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin e6. Cancer Res 1995;55:1014-1019.
49. Cavanaugh PG. Synthesis of chlorin e6-transferrin and demonstration of its light-dependent in vitro breast cancer cell killing ability. Breast Cancer Res Treat 2002;72:117-130.
50. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 2002;101:78-85.
51. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004;122:1002-1011.
52. Rahimipour S, Ben-Aroya N, Ziv K, Chen A, Fridkin M, Koch Y. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J Med Chem 2003;46:3965-3974.
53. Zhang M, Zhang Z, Blessington D, Li H, Busch TM, Madrak V, Miles J, Chance B, Glickson JD, Zheng G. Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters. Bioconjug Chem 2003;14:709-714.
54. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: A remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29:339-343.
55. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4:397-410.
56. Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 1995;7:19-29.
57. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC. P-glycoprotein targeting: A unique strategy to selectively eliminate immunoreactive T cells. Blood 2002;100:375-382.
58. Demidova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol 2004;17:117-126.
59. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: A randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004;20:1289-1296.
60. Waidelich R, Beyer W, Knuchel R, Stepp H, Baumgartner R, Schroder J, Hofstetter A, Kriegmair M. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003;61:332-337.
61. Marks PV, Belchetz PE, Saxena A, Igbaseimokumo U, Thomson S, Nelson M, Stringer MR, Holroyd JA, Brown SB. Effect of photodynamic therapy on recurrent pituitary adenomas: Clinical phase I/II trial-an early report. Br J Neurosurg 2000;14:317-325.
62. Zimmermann A, Ritsch-Marte M, Kostron H. mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 2001;74:611-616.
63. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000;60:4066-4069.
64. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002;62:3956-3961.
65. Ferrario A, Fisher AM, Rucker N, Gomer CJ. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005;65:9473-9478.